APA (7th ed.) Citation

X, S., R, d., E, L., P, L., T, M., PM, M., . . . A, B. (2025). Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial. Human vaccines & immunotherapeutics, 21(1), 2450878. https://doi.org/10.1080/21645515.2025.2450878

Chicago Style (17th ed.) Citation

X, Sáez-Llorens, deAntonio R, López-Medina E, López P, Masuda T, Mendelman PM, Sherwood J, Baehner F, and Borkowski A. "Safety and Immunogenicity of a Bivalent Norovirus Vaccine Candidate in Infants from 6 Weeks to 5 Months of Age: A Phase 2, Randomized, Double-blind Trial." Human Vaccines & Immunotherapeutics 21, no. 1 (2025): 2450878. https://doi.org/10.1080/21645515.2025.2450878.

MLA (9th ed.) Citation

X, Sáez-Llorens, et al. "Safety and Immunogenicity of a Bivalent Norovirus Vaccine Candidate in Infants from 6 Weeks to 5 Months of Age: A Phase 2, Randomized, Double-blind Trial." Human Vaccines & Immunotherapeutics, vol. 21, no. 1, 2025, p. 2450878, https://doi.org/10.1080/21645515.2025.2450878.